亚太药业(002370) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue decreased by 49.10% to CNY 150,885,573.26 for the current period compared to the same period last year[7]. - Net profit attributable to shareholders was CNY -33,330,515.92, a decline of 194.63% year-on-year[7]. - Basic earnings per share were CNY -0.06, down 185.71% from the previous year[7]. - Net profit decreased by 95.89% year-on-year, mainly due to a reduction in operating income[16]. - Operating cash flow net amount decreased by 640.47% year-on-year, primarily due to a decrease in cash received from sales of goods and services[16]. - The total operating revenue for Q3 2019 was CNY 150,885,573.26, a decrease of 49% compared to CNY 296,458,738.80 in the same period last year[46]. - Net profit for Q3 2019 was a loss of CNY 33,389,014.26, compared to a profit of CNY 35,314,260.83 in Q3 2018[47]. - The company's operating profit decreased to CNY 4,581,023.25 from CNY 20,812,748.72, marking a decline of approximately 78%[50]. - The total comprehensive income for the period was CNY -33,389,014.26, contrasting with CNY 35,462,265.89 in the previous year[50]. - The net profit for Q3 2019 was CNY 3,404,699.91, a significant decrease of 81.9% compared to CNY 18,766,404.09 in Q3 2018[50][52]. Assets and Liabilities - Total assets increased by 34.16% to CNY 4,423,602,030.98 compared to the end of the previous year[7]. - The company's total assets as of September 30, 2019, amounted to CNY 3,225,456,545.08, an increase from CNY 2,265,925,534.69 at the end of 2018[44]. - The total liabilities reached CNY 1,714,528,136.28, compared to CNY 773,072,849.17 at the end of 2018[38]. - The company's long-term borrowings increased to CNY 270,000,000.00 from CNY 164,600,000.00[38]. - The total liabilities amounted to CNY 773,072,849.17, with total equity at CNY 2,524,154,329.98, resulting in total assets of CNY 3,297,227,179.15[73]. - The company's current assets totaled CNY 1,110,522,958.58, significantly up from CNY 490,054,412.75 year-on-year[42]. - The total owner's equity attributable to shareholders was CNY 2,512,310,609.62, with retained earnings of CNY 606,951,794.75[73]. Cash Flow - Net cash flow from operating activities was CNY -10,063,166.52, representing a 64.99% decrease compared to the same period last year[7]. - Cash and cash equivalents increased by 137.47% compared to the end of the previous year, mainly due to the proceeds from the public issuance of convertible bonds[15]. - Cash flow from operating activities showed a net outflow of CNY 40,823,667.36, compared to a net inflow of CNY 7,553,432.27 in the previous period[63]. - Cash flow from investing activities showed a net outflow of CNY 312,974,308.76, compared to a net inflow of CNY 80,262,704.83 in the previous period, indicating increased investment expenditures[68]. - Cash flow from financing activities resulted in a net inflow of CNY 925,763,484.76, a recovery from a net outflow of CNY 53,649,445.60 in the previous period[68]. Shareholder Information - The total number of shareholders at the end of the reporting period was 36,862[11]. - Zhejiang Apac Group Co., Ltd. held 20.15% of the shares, making it the largest shareholder[11]. - Shareholders plan to reduce their holdings by up to 1.6 million shares through various methods, with no reductions made as of the report date[19]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 17,076,989.68 during the reporting period[8]. - Other income increased by 166.65% year-on-year, mainly due to an increase in government subsidies received[16]. Management and Compliance - The company discovered a violation of external guarantees by its subsidiary, which was not approved through normal procedures[18]. - The company has made commitments regarding shareholding and management practices to ensure compliance and protect shareholder interests[23]. - The company has committed to not engage in similar business activities as Zhejiang Apac Pharmaceutical Co., Ltd. for a period of 36 months following its stock listing[22]. Financial Expenses - Financial expenses increased by 233.45% year-on-year, mainly due to increased interest expenses on bank loans and accrued interest on convertible bonds[16]. - The company reported a financial expense of CNY 31,052,117.89 for the year-to-date, significantly higher than CNY 9,312,450.02 in the same period last year[53]. Research and Development - Research and development expenses for Q3 2019 were CNY 11,701,558.12, down from CNY 16,671,349.31 in the previous year[46]. - Research and development expenses decreased to CNY 21,223,667.43, down 26.8% from CNY 28,963,613.22 in the previous period[59].